Journal Article

Psychotropic medication use in parents of survivors of adolescent cancer: A register‐based cohort study

Alvariza, Anette, Skoglund, Charlotte, Ljungman, Lisa, Ljungman, Gustaf, Ljung, Rickard, Hovén, Emma, Lövgren, Malin, Kreicbergs, Ulrika, Wikman, Anna, Fransson, Emma

2022

Overview

Background The aim was to investigate psychotropic medication use in parents of survivors of adolescent cancer from the acute post‐diagnostic phase and up to 2 years following the cancer diagnosis. Methods This study had a nationwide register‐based cohort design comparing psychotropic medication use in parents of adolescent survivors of cancer (n = 2323) to use in parents of cancer‐free controls (n = 20,868). Cox proportional hazards models, adjusted for cancer diagnostic group, parents' age, country of birth, education level, marital status and previous mental health problems estimated the risk of use from the time of the cancer diagnosis up to 2 years later. Results During the first 6 months after the cancer diagnosis, both mothers and fathers had an increased risk of use of anxiolytics (mothers: HRadj 1.71, 95% CI 1.30–2.25; fathers: HRadj 1.57, 95% CI 1.10–2.45) and hypnotics/sedatives (mothers: HRadj 1.53, 95% CI 1.23–1.90; fathers: HRadj 1.32, 95% CI 1.00–1.75). For fathers with a prescription of psychotropic medication during the first 6 months after the cancer diagnosis, the risk remained increased after 6 months (HRadj 1.66, 95% CI 1.04–2.65). From 6 months after the cancer diagnosis, only the risk of antidepressant use among mothers was increased (HRadj 1.38, 95% CI 1.08–1.76). Risk factors included being divorced/widowed, born in a non‐Nordic country, older age and having had previous mental health problems. Conclusion Our study results show that during the immediate post‐diagnostic phase, mothers and fathers of survivors of adolescent cancer are at increased risk of use of anxiolytics and sedatives, whereas only mothers are at increased risk of antidepressant use from 6 months until 2 years after the diagnosis. Further, previous mental health problems were shown to be the strongest risk factor for psychotropic medication use in both mothers and fathers, pointing to the particular vulnerability of these parents. Using high quality register data this study show that both mothers and fathers of adolescents diagnosed with cancer are at increased risk use anxiolytics and sedatives, pointing to clinical levels of anxiety and sleep disturbances, during the first six months after the cancer diagnosis. Also, from six months until two years after the cancer diagnosis mothers were at increased risk of antidepressant use.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• Subject: Adolescence / Adolescent / Anesthesia / Anti-Anxiety Agents - therapeutic use / Antidepressants / Antidepressive Agents - therapeutic use / Anxiety / Anxiolytics / Cancer / Cancer therapies / Child development / Childhood cancer / Children & youth / Cohort analysis / Cohort Studies / Confidence intervals / Diagnosis / Humans / Hypnotics / Hypnotics and Sedatives / Hypnotics/sedatives / Medical diagnosis / Mental depression / Mental disorders / Mental health / Mental health problems / Mothers / Neoplasms - drug therapy / Neoplasms - epidemiology / Parents / Parents & parenting / Parents - psychology / Patients / Population / Psychological distress / Psychotropic drugs / Risk factors / Sedatives / Survivors / Teenagers / Tranquilizers / Tumors